NO20022886D0 - Nye lipopeptider som antibakterielle midler - Google Patents

Nye lipopeptider som antibakterielle midler

Info

Publication number
NO20022886D0
NO20022886D0 NO20022886A NO20022886A NO20022886D0 NO 20022886 D0 NO20022886 D0 NO 20022886D0 NO 20022886 A NO20022886 A NO 20022886A NO 20022886 A NO20022886 A NO 20022886A NO 20022886 D0 NO20022886 D0 NO 20022886D0
Authority
NO
Norway
Prior art keywords
antibacterial agents
new lipopeptides
lipopeptides
new
antibacterial
Prior art date
Application number
NO20022886A
Other languages
English (en)
Other versions
NO20022886L (no
Inventor
Jason Hill
Ian Parr
Michael Morytko
Jim Siedlecki
Xiang Yang Yu
Jared Silverman
Dennis Keith
John Finn
Dale Christensen
Tsvetelina Lazarova
Alan D Watson
Yan Zhang
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of NO20022886D0 publication Critical patent/NO20022886D0/no
Publication of NO20022886L publication Critical patent/NO20022886L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20022886A 1999-12-15 2002-06-17 Nye lipopeptider som antibakterielle midler NO20022886L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17094599P 1999-12-15 1999-12-15
PCT/US2000/034051 WO2001044271A2 (en) 1999-12-15 2000-12-15 Daptomycin analogs and their use as antibacterial agents

Publications (2)

Publication Number Publication Date
NO20022886D0 true NO20022886D0 (no) 2002-06-17
NO20022886L NO20022886L (no) 2002-08-02

Family

ID=22621920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022886A NO20022886L (no) 1999-12-15 2002-06-17 Nye lipopeptider som antibakterielle midler

Country Status (13)

Country Link
US (1) US6794490B2 (no)
EP (1) EP1240182A2 (no)
JP (1) JP2003517003A (no)
KR (1) KR20020063230A (no)
CN (1) CN1423655A (no)
AU (1) AU784942B2 (no)
BR (1) BR0017028A (no)
CA (1) CA2394313A1 (no)
IL (1) IL150224A0 (no)
MX (1) MXPA02006028A (no)
NO (1) NO20022886L (no)
WO (1) WO2001044271A2 (no)
ZA (1) ZA200205113B (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016467A (pt) * 1999-12-15 2002-08-27 Cubist Pharm Inc Lipopeptìdeos como agentes antibacterianos
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
NZ571597A (en) 2000-12-18 2010-05-28 Cubist Pharm Inc Method for preparing crystalline and crystal-like forms of purified daptomycin lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
DE60232158D1 (de) 2001-08-06 2009-06-10 Cubist Pharm Inc Lipopeptid-stereoisomere, verfahren zu ihrer herstellung und nützliche zwischenprodukte
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
US6767718B2 (en) 2002-05-10 2004-07-27 Biosource Pharm, Inc. Lipodepsipeptide antibiotics and methods of preparation
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
AU2003240545A1 (en) 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
CA2529125A1 (en) * 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
EP1675548A4 (en) * 2003-09-25 2008-08-13 Activbiotics Inc RIFALAZIL FORMULATIONS
US20080019955A1 (en) * 2003-12-30 2008-01-24 Bioactive Polymers Ab Surface Protection of Exposed Biological Tissues
SE0303588D0 (sv) 2003-12-30 2003-12-30 Bioactive Polymers Ab C O Lund Surface protection of exposed biological tissues
US8782654B2 (en) 2004-03-13 2014-07-15 Adaptive Computing Enterprises, Inc. Co-allocating a reservation spanning different compute resources types
US8413155B2 (en) 2004-03-13 2013-04-02 Adaptive Computing Enterprises, Inc. System and method for a self-optimizing reservation in time of compute resources
US20070266388A1 (en) 2004-06-18 2007-11-15 Cluster Resources, Inc. System and method for providing advanced reservations in a compute environment
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US8176490B1 (en) 2004-08-20 2012-05-08 Adaptive Computing Enterprises, Inc. System and method of interfacing a workload manager and scheduler with an identity manager
WO2006053093A2 (en) 2004-11-08 2006-05-18 Cluster Resources, Inc. System and method of providing system jobs within a compute environment
CA2587848A1 (en) * 2004-11-12 2006-10-19 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
JP2008534444A (ja) * 2005-03-10 2008-08-28 スミスクライン・ビーチャム・コーポレイション 新規な方法
US8863143B2 (en) 2006-03-16 2014-10-14 Adaptive Computing Enterprises, Inc. System and method for managing a hybrid compute environment
WO2006107531A2 (en) 2005-03-16 2006-10-12 Cluster Resources, Inc. Simple integration of an on-demand compute environment
US9231886B2 (en) 2005-03-16 2016-01-05 Adaptive Computing Enterprises, Inc. Simple integration of an on-demand compute environment
CA2603577A1 (en) 2005-04-07 2006-10-12 Cluster Resources, Inc. On-demand access to compute resources
AU2006242535B2 (en) * 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
US8041773B2 (en) 2007-09-24 2011-10-18 The Research Foundation Of State University Of New York Automatic clustering for self-organizing grids
PL2379580T3 (pl) * 2008-12-22 2014-05-30 Merck Sharp & Dohme Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi
NZ593892A (en) 2008-12-23 2013-11-29 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
US10877695B2 (en) 2009-10-30 2020-12-29 Iii Holdings 2, Llc Memcached server functionality in a cluster of data processing nodes
US11720290B2 (en) 2009-10-30 2023-08-08 Iii Holdings 2, Llc Memcached server functionality in a cluster of data processing nodes
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012011917A1 (en) * 2010-07-23 2012-01-26 Activbiotics Pharma, Llc Administration of rifalazil to immunocompromised patients
MX2013013760A (es) * 2011-05-26 2014-01-08 Cubist Pharm Inc Composiciones de cb-183, 315 y metodos relacionados.
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
US10358463B2 (en) * 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EP3571223B1 (en) 2017-01-18 2024-09-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018237153A1 (en) * 2017-06-23 2018-12-27 Bristol-Myers Squibb Company IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS
JP2023521319A (ja) 2020-04-03 2023-05-24 ビステラ， インコーポレイテッド 抗体分子－薬物コンジュゲートおよびその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68700A0 (en) 1982-05-21 1983-09-30 Lilly Co Eli Improvements relating to a-21978c cyclic peptide derivatives and their production
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4399067A (en) 1982-05-21 1983-08-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4396543A (en) 1982-05-21 1983-08-02 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
ES2089133T3 (es) 1990-06-07 1996-10-01 Lilly Co Eli Desacilasa de lipopeptidos.
DE4411025A1 (de) 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
ATE544851T1 (de) 1996-03-08 2012-02-15 Astellas Pharma Inc Verfahren zur deacylierung von zyklischen lipopeptiden
DE19807972A1 (de) 1998-02-25 1999-08-26 Hoechst Marion Roussel De Gmbh Lipopeptidantibiotika-Calciumsalze, Verfahren zu ihrer Herstellung und Verwendung

Also Published As

Publication number Publication date
JP2003517003A (ja) 2003-05-20
AU3264001A (en) 2001-06-25
WO2001044271A2 (en) 2001-06-21
NO20022886L (no) 2002-08-02
CA2394313A1 (en) 2001-06-21
MXPA02006028A (es) 2004-08-23
KR20020063230A (ko) 2002-08-01
BR0017028A (pt) 2003-01-07
US6794490B2 (en) 2004-09-21
EP1240182A2 (en) 2002-09-18
US20020058785A1 (en) 2002-05-16
CN1423655A (zh) 2003-06-11
AU784942B2 (en) 2006-08-03
ZA200205113B (en) 2003-11-26
WO2001044271A3 (en) 2002-03-07
IL150224A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
NO20022886L (no) Nye lipopeptider som antibakterielle midler
NO20022888D0 (no) Nye lipopeptider som antibakterielle midler
NO20022887L (no) Lipopeptider som antibakterielle midler
NO20031001D0 (no) Polyarylkarboksamider nyttige som lipidsenkende midler
NO20033715L (no) Nye sammensetninger
NO20011738D0 (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20015855L (no) Ny anvendelse av forbindelser som antibakterielle midler
NO20035193L (no) Nye pyrrolderivater som farmas degree ytiske midler
NO20022502L (no) Nye antidiabetiske midler
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
DK1326858T3 (da) Piperidinforbindelser som anti-allergiske midler
DK1028961T3 (da) Pleuromutilinderivater som antimikrobielle midler
NO20020810D0 (no) Nye fenylpiperaziner
NO20015074L (no) Nye sammensetninger
NO20032272D0 (no) Bifenylkarboksamider nyttige som lipidsenkende midler
NO20024745L (no) 2-hydroksymutilinkarbamat-derivater for antibakteriell anvendelse
NO20030100L (no) Pleuromutilinderivater som har antibakteriell aktivitet
DK1181288T3 (da) Bicycliske oxazolidinoner som antibakterielle midler
DK1246810T3 (da) Piperidinyloxy- og pyrrolidinyloxyphenyloxazolidinoner som antibakterielle midler
NO20020621D0 (no) Antibakterielle midler
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application